0.74 USD
▲+0.03+1.38%
盘后 0.70 -4.78%
2026-08-03
市值
$23.45M
市盈率
—
EPS
-1.12
股息率
—
52 周区间
0.48 – 1.75
成交量
777.96K
Beta
-0.25
目标价
7.15
52W 低 0.4852W 高 1.75
价格走势
公司简介
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated...